The effect of statins on DVT was brought to light in 2009 through a clinical randomized
controlled trial (RCT) called the JUPITER Trial. In this study, relatively healthy people with high levels of C-reactive protein (CRP) and normal low density lipoprotein cholesterol(LDL-C) levels, were given either a placebo or rosuvastatin [9]. It showed that the rate of DVT was significantly decreased in patients treated with rosuvastatin versus controls, 34 versus 60 patients respectively, with a median follow-up point of 1.9 years [9]. Rosuvastatin,along with other statins, inhibits hydroxymethylglutaryl (HMG)-CoA reductase, and are used as a treatment for hypercholesterolemia.
The effect of statins on DVT was brought to light in 2009 through a clinical randomizedcontrolled trial (RCT) called the JUPITER Trial. In this study, relatively healthy people with high levels of C-reactive protein (CRP) and normal low density lipoprotein cholesterol(LDL-C) levels, were given either a placebo or rosuvastatin [9]. It showed that the rate of DVT was significantly decreased in patients treated with rosuvastatin versus controls, 34 versus 60 patients respectively, with a median follow-up point of 1.9 years [9]. Rosuvastatin,along with other statins, inhibits hydroxymethylglutaryl (HMG)-CoA reductase, and are used as a treatment for hypercholesterolemia.
การแปล กรุณารอสักครู่..
